REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New bridge therapy aims to get more patients to lifesaving CAR-T treatment
Disease control Recruiting nowThis study is testing a drug called odronextamab to see if it can help control aggressive lymphoma long enough for patients to receive CAR-T cell therapy, a potentially curative treatment. The drug is given before the process to collect immune cells for CAR-T begins, with the goa…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New bridge to a cancer cure: drug combo aims to get more patients to Life-Saving CAR-T
Disease control Recruiting nowThis study is testing a two-drug combination (golcadomide and rituximab) as a 'bridging therapy' for adults with aggressive B-cell lymphoma that has returned or not responded to prior treatment. The goal is to control the cancer and improve patients' health so they can qualify fo…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New Two-Pronged attack tested for Tough-to-Treat lymphoma that returns
Disease control Recruiting nowThis study is testing a new treatment sequence for adults whose aggressive large B-cell lymphoma has come back or didn't respond to initial therapy. Participants first receive two targeted drugs (tafasitamab and lenalidomide), followed by a stronger chemotherapy regimen. The main…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New immune therapy trial aims to control Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing whether adding a new immune-boosting drug called epcoritamab to standard chemotherapy and a stem cell transplant can better control aggressive large B-cell lymphoma that has returned or not responded to prior treatment. It will involve about 25 adults whose …
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New 5-Drug attack on Tough-to-Treat blood cancers
Disease control Recruiting nowThis study is testing a combination of five medications (called ViPOR) for people with aggressive types of B-cell lymphoma that have returned after treatment or did not respond to prior therapy. The goal is to see if this drug combination can effectively control the cancer and le…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New combo therapy aims to boost Cancer-Killing power of CAR-T
Disease control Recruiting nowThis early-phase study is testing the safety and effectiveness of a new drug called ST-067 when given alongside a personalized immune cell therapy (CAR-T) for patients with aggressive large B-cell lymphoma that has come back or not responded to other treatments. The goal is to se…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 17, 2026 13:08 UTC